Suzhou Puhe Biopharma Co., Ltd., established in April 2021, represents a collaborative effort between leading domestic medical enterprises and Shiyu Investment, a fund specializing in the pharmaceutical industry. Our core focus is on the development of innovative small molecule drugs in oncology and supportive cancer care. We aspire to be a pioneering BioPharma company with a base in China and a global reach.
Our strategy is to address distinct clinical needs. That's why we focuses on lung cancer, pancreatic cancer, gastrointestinal tumors and other cancer types with high morbidity and mortality rates worldwide. We employ a strategic approach that combines scientific acumen and industrial foresight. Our methods include introducing and developing innovative drug projects, alongside leveraging various means to expand our development opportunities. We are committed to accelerating the industrialization of our company by integrating resources efficiently.
At the heart of our approach are molecular targets, around which we have established a robust platform for developing unique small molecule drugs. This platform integrates advanced technologies like new-generation kinase inhibitors, allosteric inhibitors, synthetic lethality approaches, and Proteolysis targeting chimeras (Protacs) to address complex challenges. Our capabilities span a wide range, from target discovery and molecular structure design to in vivo and in vitro activity assessments, safety and pharmacokinetics evaluations, regulatory submissions, and the initiation of clinical trials across phases I, II, and III, culminating in product production.

Driven by innovation, grounded in scientific understanding, and focused on clinical needs.
We concentrate on the research and development of new drugs in key areas of disease, particularly in oncology and supportive cancer therapies.